Ask a doctor about a prescription for SUBOXONE 4 mg/1 mg SUBLINGUAL FILM-COATED TABLETS
Package Leaflet: Information for the User
Suboxone 2 mg/0.5 mg sublingual film
Suboxone 4 mg/1 mg sublingual film
Suboxone 8 mg/2 mg sublingual film
Suboxone 12 mg/3 mg sublingual film
buprenorphine/naloxone
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Suboxone is used to treat opioid dependence (narcotics), such as heroin ormorphine, in patients whohave given their consent to be treated for their addiction.
Suboxone is used in adults and adolescents over 15 yearswho are also receiving medical, social, and psychological support.
Do not take Suboxone
Warnings and precautions
Consult your doctor before taking Suboxone if you have:
Important things to consider:
If you are over 65 years old, your doctor may monitor you more closely.
This medicine may be targeted by people who abuse prescription medicines and should be kept in a safe place to protect it from theft (see section 5). Do not give thismedicine to anyone else. It may cause them to die or have other serious problems.
Some people have died from respiratory failure (inability to breathe) because they used buprenorphine improperly or took it with other central nervous system depressants, such as alcohol, benzodiazepines (tranquilizers), or other opioids.
This medicine can cause severe respiratory depression (difficulty breathing) in children and non-dependent persons if they ingest it accidentally or intentionally.
This medicine can cause dependence.
This medicine can cause opioid withdrawal symptoms if you take it too soon after using opioids. You should wait at least 6 hours after using a short-acting opioid (e.g., morphine, heroin) or at least 24 hours after using a long-acting opioid, such as methadone.
This medicine can also cause withdrawal symptoms if you stop taking it suddenly. See section 3 "If you stop treatment".
There have been reports of liver damage after taking Suboxone, especially when the medicine is misused. It may also be due to viral infections (e.g., chronic hepatitis C), alcohol abuse, anorexia, or the use of other medicines that can damage the liver (see section 4). Your doctor may performblood tests frequently to monitor the condition of your liver. Inform your doctor if you have any liver problems before starting treatment with Suboxone.
This medicine can cause a sudden drop in blood pressure, making you feel dizzy if you get up too quickly after sitting or lying down.
This medicine can mask the symptoms of pain that could help in the diagnosis of some diseases. You should inform your doctor that you are taking this medicine.
Children and adolescents
Do notgive this medicine to children under 15 years. If you are between 15 and 18 years old, your doctor may monitor you more closely during treatment due to the lack of data in this age group.
Other medicines and Suboxone
Inform your doctor if you are taking, have recently taken, or might take any other medicines.
Some medicines can increase the adverse effects of Suboxone and may be serious. Do not take other medicines at the same time as Suboxone without consulting your doctor first, especially:
However, if your doctor prescribes Suboxone with sedatives, your doctor should limit the dose and duration of concomitant treatment.
Inform your doctor about all sedatives you are taking and strictly follow your doctor's dosage recommendation. It may be useful to inform your friends or family to be alert to the signs and symptoms mentioned above. Contact your doctor if you experience these symptoms.
Using Suboxone with food, drinks, and alcohol
Do not drink alcoholwhile you are being treated with this medicine. Alcohol may increase drowsiness and the risk of respiratory failure if taken with Suboxone. Do not swallow or consume food or drinks until the film has dissolved completely.
Pregnancy, breastfeeding, and fertility
Inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. The risks of using Suboxone in pregnant women are not known. Your doctor will decide whether you should continue your treatment with another medicine.
When taken during pregnancy, especially in the last months, medicines like Suboxone can cause withdrawal symptoms in the newborn, including breathing problems. This can occur several days after birth.
Do not breastfeed while taking this medicine, as buprenorphine is excreted in breast milk.
Consult your doctor or pharmacist before taking any medicine.
Driving and using machines
Do notdrive or ride a bike, do notuse tools or machines, do notengage in hazardous activities until you know how this medicine affects you. Suboxone can cause drowsiness, dizziness, or altered thinking. This can occur more frequently in the first weeks of treatment, when the dose is being changed, but it can also occur if you drink alcohol or take other sedative medicines at the same time as taking Suboxone.
Suboxone contains maltitol, orange yellow S (E-110), and sodium.
Suboxone contains liquid maltitol. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Suboxone contains orange yellow S (E-110), which may cause allergic reactions.
This medicine contains less than 1 mmol of sodium (23 mg) per film; i.e., it is essentially "sodium-free".
Follow your doctor's or pharmacist's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
Treatment is prescribed and supervised by doctors with experience in treating drug addiction.
Your doctor will determine the best dose for you. During treatment, your doctor may adjust your dose based on your response to treatment.
Starting Treatment
The recommended initial dose in adults and adolescents over 15 years is normally two Suboxone 2 mg/0.5 mg sublingual films or one Suboxone 4 mg/1 mg sublingual film.
This dose may be repeated two more times on Day 1, depending on your needs.
Before taking your first dose of Suboxone, you must be experiencing clear signs of withdrawal. Your doctor will tell you when to take your first dose.
If you have heroin or short-acting opioid dependence, the first dose should be taken when signs of withdrawal appear, at least 6 hours after the last time you used opioids.
If you have been taking methadone or a long-acting opioid, it is recommended to reduce the methadone dose to less than 30 mg/day before starting treatment with Suboxone. The first dose of Suboxone should be taken when signs of withdrawal appear and at least 24 hours after the last time you used methadone.
Dose Adjustment and Maintenance Treatment:During the days following the start of treatment, your doctor may increase the dose of Suboxone you take according to your needs. If you think the effect of Suboxone is too strong or too weak, inform your doctor or pharmacist. The maximum daily dose is 24 mg of buprenorphine.
After a period of satisfactory treatment, you may agree with your doctor to gradually decrease the dose to a lower maintenance dose.
How to Take Suboxone
How to Remove the Film from the Pouch
Each Suboxone film comes in a child-resistant pouch. Do not open the pouch until you are ready to use it.
To open the pouch, locate the perforated line on the top edge of the pouch and fold the edge of the pouch along this line (see Figure 1).
Figure 1
Figure 2
If the pouch is damaged, discard the film.
How to Place a Film Under Your Tongue (Sublingually):
First, drink water to moisten your mouth. This helps the film dissolve more easily. Then, hold the film between two fingers by the outer edges, and place it under your tongue, near the base, either on the right or left side (see Figure 3).
Figure 3
If your doctor has instructed you to take two films at the same time, place the second film under your tongue on the other side. Make sure the films do not overlap.
If your doctor has instructed you to take a third film, place it under your tongue on either side after the first two have dissolved.
How to Place a Film Inside Your Cheek (Buccally):
Drink water to moisten your mouth. Hold the film between two fingers by the outer edges, and place it inside your cheek, either on the right or left side (see Figure 4).
Figure 4
If your doctor has instructed you to take two films at the same time, place the second film inside the other cheek; this will ensure the films do not overlap. If your doctor has instructed you to take a third film, place it inside your cheek on either side after the first two have dissolved.
If You Take More Suboxone Than You Should
If you or someone else takes too much of this medication, seek urgent medical attention.
Overdose of Suboxone can cause serious and potentially life-threatening breathing problems.
Overdose symptoms may include drowsiness and disorientation with slow reflexes, blurred vision, and/or difficulty speaking. You may not be able to think clearly and may breathe much more slowly than usual for you.
If You Miss a Dose of Suboxone
If you forget to take a dose, inform your doctor as soon as possible.
If You Stop Treatment with Suboxone
Sudden interruption of treatment can cause withdrawal symptoms.Depending on your condition, the dose of Suboxone may continue to be decreased under close medical supervision until it can finally be stopped. Do not change your treatment in any way or stop it without the authorization of the doctor treating you.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone experiences them.
Tell your doctor or seek urgent medical attention immediatelyif you experience side effects such as:
Very Common Side Effects (may affect more than 1 in 10 people):
Common Side Effects (may affect up to 1 in 10 people):
Uncommon Side Effects (may affect up to 1 in 100 people):
Frequency Not Known (cannot be estimated from the available data):
Misuse of this medication by injection can cause withdrawal symptoms, infections, other skin reactions, and potentially serious liver problems (see "Warnings and Precautions").
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children and other family members. Do not use this medication after the expiration date shown on the carton and pouch. The expiration date is the last day of the month indicated.
Store below 25°C.
Suboxone may be a target for people who abuse prescription medications.
Keep this medication in a safe place to protect it from theft.
Store the pouch safely.
Never open the pouch before it is time.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medications. This will help protect the environment.
Suboxone Composition
Each 2 mg/0.5 mg film contains 2 mg of buprenorphine (as hydrochloride) and 0.5 mg of naloxone (as hydrochloride dihydrate).
Each 4 mg/1 mg film contains 4 mg of buprenorphine (as hydrochloride) and 1 mg of naloxone (as hydrochloride dihydrate).
Each 8 mg/2 mg film contains 8 mg of buprenorphine (as hydrochloride) and 2 mg of naloxone (as hydrochloride dihydrate).
Each 12 mg/3 mg film contains 12 mg of buprenorphine (as hydrochloride) and 3 mg of naloxone (as hydrochloride dihydrate).
Product Appearance and Packaging Contents
Suboxone 2 mg/0.5 mg sublingual films are orange rectangular films with nominal dimensions of 22.0 mm × 12.8 mm, with “N2” engraved in white ink.
Suboxone 4 mg/1 mg sublingual films are orange rectangular films with nominal dimensions of 22.0 mm × 25.6 mm, with “N4” engraved in white ink.
Suboxone 8 mg/2 mg sublingual films are orange rectangular films with nominal dimensions of 22.0 mm × 12.8 mm, with “N8” engraved in white ink.
Suboxone 12 mg/3 mg sublingual films are orange rectangular films with nominal dimensions of 22.0 mm × 19.2 mm, with “N12” engraved in white ink.
The films are packaged in individual pouches.
Package sizes: boxes containing 7 × 1, 14 × 1, and 28 × 1 films.
Only some package sizes may be marketed.
Marketing Authorization Holder
Indivior Europe Limited
27 Windsor Place
Dublin 2
Ireland
Manufacturer
Almac Pharma Services Limited
Seagoe Industrial Estate, Portadown
Craigavon BT63 5UA
United Kingdom
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate, Dundalk
Co. Louth A91 P9KD
Ireland
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium Indivior Europe Limited Tel: 0800 780 41 e-mail: PatientSafetyRow@indivior.com | Lithuania Indivior Europe Limited Tel: 880030793 e-mail: PatientSafetyRoW@indivior.com |
Greece Indivior Europe Limited Tel: 00800 110 4104 e-mail: PatientSafetyRoW@indivior.com | Luxembourg Indivior Europe Limited Tel: 800 245 43 e-mail: PatientSafetyRow@indivior.com |
Czech Republic Indivior Europe Limited Tel: 800 143 737 e-mail: PatientSafetyRoW@indivior.com | Hungary Indivior Europe Limited Tel: 6800 19301 e-mail: PatientSafetyRoW@indivior.com |
Denmark Indivior Europe Limited Tlf: 80826653 e-mail: PatientSafetyRoW@indivior.com | Malta Indivior Europe Limited Tel: 80062185 e-mail: PatientSafetyRoW@indivior.com |
Germany Indivior Europe Limited Tel: 800 181 3799 e-mail: PatientSafetyRoW@indivior.com | Netherlands Indivior Europe Limited Tel: 0800 022 87 83 e-mail: PatientSafetyRow@indivior.com |
Estonia Indivior Europe Limited Tel: 8000041004 e-mail: PatientSafetyRoW@indivior.com | Norway Indivior Europe Limited Tlf: 80016773 e-mail: PatientSafetyRoW@indivior.com |
Greece Indivior Europe Limited Tel: 800 270 81 901 e-mail: PatientSafetyRoW@indivior.com | Austria Indivior Europe Limited Tel: 800 296551 e-mail: PatientSafetyRoW@indivior.com |
Spain Indivior Europe Limited Tel: 900 994 121 e-mail: PatientSafetyRoW@indivior.com | Poland Indivior Europe Limited Tel: 0800 4111237 e-mail: PatientSafetyRoW@indivior.com |
France Indivior Europe Limited Tel: 0800 909 972 e-mail: PatientSafetyFrance@indivior.com | Portugal Indivior Europe Limited Tel: 800 841 042 e-mail: PatientSafetyRoW@indivior.com |
Croatia Indivior Europe Limited Tel: + 0800 222 899 e-mail: PatientSafetyRoW@indivior.com | Romania Indivior Europe Limited Tel: 800 477 029 e-mail: PatientSafetyRoW@indivior.com |
Ireland Indivior Europe Limited Tel: 1800554156 e-mail: PatientSafetyRoW@indivior.com | Slovenia Indivior Europe Limited Tel: 080080715 e-mail: PatientSafetyRoW@indivior.com |
Iceland Indivior Europe Limited Phone: 8009875 e-mail: PatientSafetyRoW@indivior.com | Slovakia Indivior Europe Limited Tel: 800110286 e-mail: PatientSafetyRoW@indivior.com |
Italy Indivior Europe Limited Tel: 800 789 822 e-mail: PatientSafetyRoW@indivior.com | Finland Indivior Europe Limited Phone/Tel: 0800417489 e-mail: PatientSafetyRoW@indivior.com |
Cyprus Indivior Europe Limited Tel: 800 270 81 901 e-mail: PatientSafetyRoW@indivior.com | Sweden Indivior Europe Limited Tel: 020791680 e-mail: PatientSafetyRoW@indivior.com |
Latvia Indivior Europe Limited Tel: 800 05612 e-mail: PatientSafetyRoW@indivior.com | United Kingdom Indivior Europe Limited Tel: 0808 234 9243 e-mail: PatientSafetyRoW@indivior.com |
Date of Last Revision of this Leaflet:{month YYYY}.
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SUBOXONE 4 mg/1 mg SUBLINGUAL FILM-COATED TABLETS – subject to medical assessment and local rules.